Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
Pacira BioSciences (NASDAQ:PCRX) was upgraded by analysts at Barclays PLC to a "hold" rating.
Pacira BioSciences (NASDAQ:PCRX) had its "sell (d+)" rating reaffirmed by analysts at
Weiss Ratings.
Pacira BioSciences (NASDAQ:PCRX) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $27.00 price target on the stock.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)